These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 21731887)

  • 41. Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.
    Dhillon S
    Drugs; 2013 Sep; 73(13):1451-62. PubMed ID: 23881669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of aldosterone blockers in the management of chronic heart failure.
    Coca SG; Perazella MA
    Am J Med Sci; 2005 Oct; 330(4):176-83. PubMed ID: 16234610
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Eplerenone: a new selective aldosterone receptor antagonist.
    Weinberger MH
    Drugs Today (Barc); 2004 Jun; 40(6):481-5. PubMed ID: 15349128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard?
    Jewell CW; Watson LE; Mock J; Dostal DE
    Cardiovasc Hematol Agents Med Chem; 2006 Apr; 4(2):129-53. PubMed ID: 16611048
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eplerenone: a selective aldosterone blocker.
    Stier CT
    Cardiovasc Drug Rev; 2003; 21(3):169-84. PubMed ID: 12931252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Mineralocorticoid receptor antagonists and therapeutic strategies of cardiovascular damage].
    Verdugo FJ; Montellano FA; Carreño JE; Marusic ET
    Rev Med Chil; 2014 Jan; 142(1):61-71. PubMed ID: 24861116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients.
    Orea-Tejeda A; Colín-Ramírez E; Castillo-Martínez L; Asensio-Lafuente E; Corzo-León D; González-Toledo R; Rebollar-González V; Narváez-David R; Dorantes-García J
    Rev Invest Clin; 2007; 59(2):103-7. PubMed ID: 17633796
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Eplerenone in patients with systolic heart failure and mild symptoms.
    Zannad F; McMurray JJ; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B;
    N Engl J Med; 2011 Jan; 364(1):11-21. PubMed ID: 21073363
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction.
    Papademetriou V; Toumpourleka M; Imprialos KP; Alataki S; Manafis A; Stavropoulos K
    Curr Pharm Des; 2018; 24(46):5517-5524. PubMed ID: 30806305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aldosterone receptor antagonists for heart failure: current status, future indications.
    Pitt B; Rajagopalan S
    Cleve Clin J Med; 2006 Mar; 73(3):257-60, 264-8. PubMed ID: 16548448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aldosterone antagonists in heart failure.
    Miller SE; Alvarez RJ
    J Cardiovasc Nurs; 2013; 28(6):E47-54. PubMed ID: 23001067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eplerenone in chronic heart failure with depressed systolic function.
    Volterrani M; Iellamo F
    Int J Cardiol; 2015 Dec; 200():12-4. PubMed ID: 26044084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction.
    Wang TY; Vora AN; Peng SA; Fonarow GC; Das S; de Lemos JA; Peterson ED
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26796254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The risks and benefits of aldosterone antagonists.
    Sica DA
    Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.